NZ608070A - 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment - Google Patents
2’-fluoro substituted carba-nucleoside analogs for antiviral treatmentInfo
- Publication number
- NZ608070A NZ608070A NZ608070A NZ60807011A NZ608070A NZ 608070 A NZ608070 A NZ 608070A NZ 608070 A NZ608070 A NZ 608070A NZ 60807011 A NZ60807011 A NZ 60807011A NZ 608070 A NZ608070 A NZ 608070A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- nucleoside analogs
- fluoro substituted
- antiviral treatment
- substituted
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- -1 nucleoside phosphates Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| PCT/US2011/029441 WO2012039791A1 (en) | 2010-09-20 | 2011-03-22 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ608070A true NZ608070A (en) | 2015-11-27 |
Family
ID=47748238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ608070A NZ608070A (en) | 2010-09-20 | 2011-03-22 | 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2619206A1 (enExample) |
| JP (4) | JP2013538230A (enExample) |
| KR (1) | KR101879887B1 (enExample) |
| CN (1) | CN103108876A (enExample) |
| AP (1) | AP3699A (enExample) |
| AU (1) | AU2011306066B2 (enExample) |
| BR (1) | BR112013008017A2 (enExample) |
| CA (1) | CA2807496C (enExample) |
| CL (1) | CL2013000727A1 (enExample) |
| CO (1) | CO6680669A2 (enExample) |
| CR (1) | CR20130172A (enExample) |
| EA (1) | EA026523B1 (enExample) |
| EC (1) | ECSP13012560A (enExample) |
| IL (1) | IL225221A0 (enExample) |
| MA (1) | MA34593B1 (enExample) |
| MX (1) | MX2013003179A (enExample) |
| NZ (1) | NZ608070A (enExample) |
| PE (3) | PE20171624A1 (enExample) |
| PH (1) | PH12013500311B1 (enExample) |
| SG (1) | SG188223A1 (enExample) |
| WO (1) | WO2012039791A1 (enExample) |
| ZA (1) | ZA201301042B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2280973T3 (pl) | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| NZ599404A (en) | 2009-09-21 | 2014-02-28 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs |
| EA025311B1 (ru) | 2010-07-19 | 2016-12-30 | Гайлид Сайэнсиз, Инк. | Способы получения диастереомерно чистых фосфорамидатных пролекарств |
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| TW201306841A (zh) | 2010-12-20 | 2013-02-16 | Gilead Sciences Inc | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| HRP20180237T4 (hr) | 2011-09-16 | 2020-12-11 | Gilead Pharmasset Llc | Metode za liječenje hcv-a |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| CN104230985B (zh) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| DK3349758T3 (da) | 2015-09-16 | 2022-06-13 | Gilead Sciences Inc | Fremgangsmåder til behandling af arenaviridae-virusinfektioner |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| EP4157272B1 (en) | 2020-05-29 | 2025-07-02 | Gilead Sciences, Inc. | Remdesivir for the treatment of viral infections |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| US11926645B2 (en) * | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| EP4504341A1 (en) | 2022-04-08 | 2025-02-12 | Shy Therapeutics LLC | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| AU2023261450A1 (en) * | 2022-04-25 | 2024-11-14 | Miracure Biotechnology Limited | Nucleoside drug for treating or preventing coronavirus infection, and use thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
| DK0481214T3 (da) | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| SK11922002A3 (sk) | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20090089922A (ko) | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| MXPA03006514A (es) * | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| AU2003298658A1 (en) | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| RU2358979C2 (ru) * | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
| ES2725457T3 (es) | 2004-09-14 | 2019-09-24 | Gilead Pharmasset Llc | Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| AU2005317081A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AU2007342367B2 (en) | 2007-01-05 | 2012-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| NZ598927A (en) | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
| PL2280973T3 (pl) * | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| BRPI1013643A2 (pt) * | 2009-02-10 | 2016-04-19 | Gilead Sciences Inc | análogos de carba-nucleosídeo para tratamento antiviral |
| DK2480552T3 (en) * | 2009-09-21 | 2017-02-20 | Gilead Sciences Inc | 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
-
2011
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active Active
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active IP Right Cessation
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/en not_active Withdrawn
- 2011-03-22 PH PH1/2013/500311A patent/PH12013500311B1/en unknown
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/en not_active Ceased
- 2011-03-22 CA CA2807496A patent/CA2807496C/en active Active
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500311B1 (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| NZ599402A (en) | 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| EA201691623A1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| WO2012142523A3 (en) | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment | |
| PH12013500033A1 (en) | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | |
| NZ593647A (en) | Synthesis of purine nucleosides | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
| MX2010013768A (es) | Fosfatos ciclicos de nucleosidos. | |
| NZ631182A (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
| TW200745151A (en) | Antiviral nucleosides | |
| CA2807584C (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| NZ629428A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| ZA200904031B (en) | Chemical compounds | |
| UA117800C2 (uk) | Похідні урацилу або тиміну для лікування гепатиту с | |
| NZ593649A (en) | Nucleoside analogs | |
| EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
| GEAP202215528A (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| PE20170203A1 (es) | Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| CY1118552T1 (el) | Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10) | |
| MX2012002958A (es) | Compuestos antivirales heterociclicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20160318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2022 BY CPA GLOBAL Effective date: 20210204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2023 BY CPA GLOBAL Effective date: 20220204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2024 BY CPA GLOBAL Effective date: 20230203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240208 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250206 |